Dataiku and Bioserenity, two European based companies, have partnered to create a wearable device which is aimed to improve the diagnosis of epilepsy. Dataiku, the maker of predictive analytics software, has created a data analysis application that has been combined with a wearable device developed by Bioserenity. The result monitors patients in real-time to help doctors effectively diagnose epilepsy.
Epilepsy affects over 50 million people worldwide, or roughly 0.7% of the global population, but diagnosing and monitoring the condition can be difficult because seizures often occur in the absence of medical staff.
To help solve this issue, Dataiku and Bioserenity collaborated in June of 2015 to create a consortium called MEData.lab, whose work focuses on the evolution of the digital hospital and connected devices. MEData.Lab allows operational and reliable implementation of tools to promote the use of connected devices (IoT) in the medical community. Its main project is to revolutionize the diagnosis of epilepsy by combining online clothing technology platforms and predictive analytics.
Bioserenity has since developed a connected wearable device called NEURONAUTE, which is the first diagnostic solution for epilepsy using smart clothing, a smartphone application and a cloud platform for remote analysis and dashboard views. The system which has received CE marking in Europe, but it is not yet available in the U.S. market, will allow for a mobile and continuous electroencephalogram recording with the objective of giving neurologists a tool for reducing the time for an accurate epilepsy diagnosis.
In turn, Dataiku has delivered an analysis application that can process and analyze the incredible amount of real-time data from the NEURONAUTE devices. They designed a system that could accommodate for each of the Bioserenity units to produce 126 million measurements and 1 GB of data per unit per hour.
The platform also had to be scalable, so a system was built that could accommodate 10,000 devices running simultaneously. The end result can interpret and analyze 90 terabytes of daily data production and 10,000 BILLION daily measurements.
“The MEData.Lab project is particularly important to us because it’s enabled us to take part in the development of what could be major transformations for the healthcare industry,” said Florian Douetteau, CEO of Dataiku. “With Bioserenity, we’re showing that the appropriate use of data could lead to tomorrow’s ever more effective world of medicine and health.”
Bioserenity received ISO 13485 certification and CE marking for the Neuronaute in May of 2016 and the solution is currently being deployed in several University Hospitals across Europe.